Vasudevan A, Ip F, Liew D, van Langenberg DR, et al. The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era. Inflamm Bowel Dis 2020;26:369-379.
PMID: 31532479